Sino Medical Sciences Technology In (688108) fair value: what the stock is really worth
As of Oct 28, 2026: fair value (intrinsic value) of Sino Medical Sciences Technology In stock ¥4.23, price ¥13.50, upside -68.6%, quality 69 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 28, 2026.
How to read this chart
60‑month range ¥4.80 – ¥41.48 · fair‑value band ¥3.18 – ¥5.34 · the ¥13.50 price screens above the ¥4.23 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 28, 2026.
Follow Sino Medical Sciences Technology In in your weekly email
Every Wednesday you see whether Sino Medical Sciences Technology In is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Sino Medical Sciences Technology Inc., a medical device company, engages in the research, development, production, and distribution of interventional medical devices in China.
Show moreShow less
Its products include coronary drug stents, coronary balloons catheter, intracranial rapid exchange balloons, and intracranial drug-eluting stents, as well as transapical mitral valve replacement system.
Sino Medical Sciences Technology Inc. was incorporated in 2007 and is headquartered in Tianjin, China.
Stock analysis
Sino Medical Sciences Technology In (688108) currently trades at ¥13.50, while our model-based Fair Value estimate is ¥4.23, 68.6% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ¥5.02 per share, and 0 of the 26 models we run sit above the ¥13.50 price.
Bear case: the Earnings-Based group reads lowest at ¥1.58, and 26 of the 26 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ¥3.18 (bear) to ¥5.34 (bull), the price of ¥13.50 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 69/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Sino Medical Sciences Technology In reported revenue of 525M CNY in FY2025 versus 194M CNY in FY2021, a compound +28.2%/yr. Reported net income was 47.3M CNY in FY2025.
Key figures
Market cap 5.8B CNY (≈ $872M) Small · P/E ratio 67.5 · P/S ratio 9.84 · EPS (TTM) ¥0.2000 · Dividend yield 0.1% · Net margin 14.2% · Return on equity 9.0% · Return on assets (EBIT) −7.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 57 out of 100 (low confidence).
What moves the price
The share trades about 47% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −3% fair-value upside, at −69%, 688108 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (¥0.1300 to ¥6.92). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear¥3.18Fair Value ¥4.23Bull¥5.34
Price ¥13.50 · Upside -68.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥0.1655 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF¥4.21¥6.77¥10.9577
Residual Income¥1.61¥1.59¥1.6676
Growth DCF¥4.14¥6.32¥9.6475
All 26 models by family
DCF Models
FCF DCF¥4.21¥6.77¥10.9577
Owner Earnings¥3.38¥5.29¥8.4072
5Y Revenue Exit¥3.03¥4.34¥6.0870
5Y EBITDA Exit¥4.24¥6.92¥10.3571
5Y P/E Exit¥3.22¥4.73¥6.4868
10Y Revenue Exit¥3.39¥4.75¥6.8164
10Y EBITDA Exit¥4.18¥6.54¥10.2465
10Y P/E Exit¥3.55¥5.02¥7.1362
Earnings-Based
Graham-Dodd¥0.7700¥4.04¥5.5963
Lynch FV¥1.11¥1.58¥2.0661
PEG = 1.0¥1.11¥1.58¥2.0657
EPV¥1.84¥1.97¥2.0770
Dividend Discount
Gordon GGM¥0.0800¥0.1500¥0.200068
DDM Multi-Stage¥0.0800¥0.1300¥0.160067
Multiples
P/E Multiple¥1.87¥2.49¥3.1163
P/S Multiple¥1.44¥1.92¥2.4058
P/B Multiple¥2.43¥3.24¥4.0555
EV/EBIT¥2.43¥3.11¥3.7963
EV/EBITDA¥3.97¥5.16¥6.3564
EV/Revenue¥1.85¥2.47¥3.1052
Asset-Based
NCAV (Graham)¥0.1600¥0.2500¥0.310052
Growth DCF
Growth DCF¥4.14¥6.32¥9.6475
Rev-Margin DCF¥3.03¥4.33¥6.0870
Economic Profit
Residual Income¥1.61¥1.59¥1.6676
ROIC Compounder¥1.84¥1.97¥2.0770
Growth Earnings
Growth-Adj P/E¥1.69¥2.41¥3.1467
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.86/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+14.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.9%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.9%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−5.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−5.7%
Dividend (yield on the price)0.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−5.7% vs −2.6%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.7% → 13%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+28.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +26.6% a year for the price.
Compare Sino Medical Sciences Technology In with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 321 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score69 · Top 25%
Fair Value upside−68.6% · Bottom 25%
Profitability
Return on equity (12 months)9.0% · Above median
Return on assets3.5% · Above median
Net margin (12 months)14.2% · Above median
Operating margin (12 months)20.9% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)18.1% · Above median
Dividend yield (12 months)0.1% · Bottom 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (12 months)67.5× · Priciest 25%
P/B6.23× · Priciest 25%
P/S (12 months)9.84× · Priciest 25%
Price / free cash flow50.0× · Priciest 25%
EV/EBITDA33.9× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 8
FUTURE (revenue growth)91· sector 35
PAST (return on equity)36· sector 17
HEALTH (low debt)0· sector 98
DIVIDEND (yield)1· sector 35
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Sino Medical Sciences Technology In Fair Value". https://www.fairvalue-calculator.com/stock/688108
Frequently asked questions
Is Sino Medical Sciences Technology In (688108) overvalued or undervalued?
As of Oct 28, 2026, our model estimates a fair value of ¥4.23 versus a price of ¥13.50, about −69% upside (overvalued).
What is the fair value of 688108?
Our model-based fair value for Sino Medical Sciences Technology In is ¥4.23 (as of Oct 28, 2026), built from audited fundamentals. The current price: ¥13.50.
What is the quality score of 688108?
Sino Medical Sciences Technology In has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sino Medical Sciences Technology In (688108)?
Our model-based price target is the fair value of ¥4.23 (as of Oct 28, 2026) from 26 valuation models. Cautious scenario ¥3.18, optimistic scenario ¥5.34. It is a calculation from audited fundamentals, not an analyst target.
What is the Sino Medical Sciences Technology In stock forecast for 2026?
Our models put fair value at ¥4.23, about −69% upside versus a price of ¥13.50 (overvalued). Cautious scenario ¥3.18, optimistic scenario ¥5.34. The calculation is refreshed regularly with new filings.
What is the revenue of Sino Medical Sciences Technology In (688108)?
Sino Medical Sciences Technology In reported trailing-twelve-month revenue of about 590M CNY (latest available figure, as of Oct 28, 2026).
Does Sino Medical Sciences Technology In pay a dividend?
Sino Medical Sciences Technology In currently shows a dividend yield of 0.07% relative to its recent price (as of Oct 28, 2026).
What growth is priced into Sino Medical Sciences Technology In (688108)?
For today's price to be fair in a discounted-cash-flow model, Sino Medical Sciences Technology In would have to grow free cash flow by +28.8 % per year for five years (discount rate 10.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +9.9 % per year. As of Oct 28, 2026.
What discount rate (WACC) does the fair value of 688108 use?
Our models discount Sino Medical Sciences Technology In at 10.7 %: a base by market capitalisation (small), damped by beta 0.60, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Sino Medical Sciences Technology In that is +28.8 % per year a year over ten years, using the same discount rate (10.7 %) and the same formula as our fair value.
How much growth has Sino Medical Sciences Technology In (688108) delivered so far?
Over the past 5 years revenue at Sino Medical Sciences Technology In grew +9.9 % a year. The price currently implies +28.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Sino Medical Sciences Technology In (688108) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Sino Medical Sciences Technology In (+28.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Sino Medical Sciences Technology In (688108)?
The free-cash-flow yield on the price is 2.00 %: that much free cash flow Sino Medical Sciences Technology In produces per unit of market value. When it exceeds the discount rate of our models (10.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Sino Medical Sciences Technology In (688108)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sino Medical Sciences Technology In it is ¥4.23 per share (as of Oct 28, 2026), against a price of ¥13.50. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Sino Medical Sciences Technology In stock overvalued or undervalued in 2026?
As of Oct 28, 2026, 688108 trades above its calculated fair value: price ¥13.50, fair value ¥4.23, a gap of about −69% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688108?
No. The price is what the market pays today (¥13.50); the fair value is what the company's own numbers justify (¥4.23). For Sino Medical Sciences Technology In the two are ¥9.27 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sino Medical Sciences Technology In worth?
The market values Sino Medical Sciences Technology In at about 5.8B CNY (market capitalisation, as of Oct 28, 2026). Per share that is ¥13.50; our models calculate a fair value of ¥4.23 per share.
What do the bullish and bearish scenarios say about 688108?
Our models span a range for Sino Medical Sciences Technology In: cautious scenario ¥3.18, base ¥4.23, optimistic ¥5.34 per share (as of Oct 28, 2026, price ¥13.50). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 688108?
Sino Medical Sciences Technology In trades at a price-to-earnings ratio of 67.5 (as of Oct 28, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥4.23 is built from several models across several years. Other multiples: P/B 6.2, P/S 9.8, EV/EBITDA 33.9.
How solid is the balance sheet of Sino Medical Sciences Technology In (688108)?
Balance-sheet figures for Sino Medical Sciences Technology In (as of Oct 28, 2026): return on equity 9.0%. They feed the Quality Score of 69/100, which measures business quality independently of the share price.
How far is 688108 from its 52-week high?
Sino Medical Sciences Technology In trades at ¥13.50, about 47% below its 52-week high of ¥25.54 and 3% above the low of ¥13.13 (as of Oct 28, 2026). Distance from the high says nothing about value: that is what the fair value of ¥4.23 is for.
Which stocks are comparable to Sino Medical Sciences Technology In?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sino Medical Sciences Technology In stock attractive at the current price?
The data as of Oct 28, 2026: price ¥13.50, calculated fair value ¥4.23 (−69%), Quality Score 69/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688108 calculated?
We run Sino Medical Sciences Technology In through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥4.23, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. Sino Medical Sciences Technology In itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sino Medical Sciences Technology In (688108)?
The closing price on Oct 28, 2026 was ¥13.50. Our model-based fair value is ¥4.23, about −69% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sino Medical Sciences Technology In right now?
The price sits above even our optimistic bull case (¥5.34). The favourable scenario is already priced in. Solid but not exceptional quality (69/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Sino Medical Sciences Technology In
How large is the market capitalisation of Sino Medical Sciences Technology In (688108)?
The market capitalisation of Sino Medical Sciences Technology In is 5.8B CNY (≈ $872M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sino Medical Sciences Technology In (688108)?
The price-to-sales ratio of Sino Medical Sciences Technology In is 9.84 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sino Medical Sciences Technology In (688108)?
Earnings per share at Sino Medical Sciences Technology In are ¥0.2000 (price ÷ EPS = P/E 67.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Sino Medical Sciences Technology In (688108)?
The dividend yield of Sino Medical Sciences Technology In is 0.1% (payout 5.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Sino Medical Sciences Technology In (688108)?
The net margin of Sino Medical Sciences Technology In is 14.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sino Medical Sciences Technology In (688108)?
The return on equity (ROE) of Sino Medical Sciences Technology In is 9.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sino Medical Sciences Technology In (688108)?
On an EBIT basis the return on assets of Sino Medical Sciences Technology In is −7.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sino Medical Sciences Technology In (688108)?
The operating margin of Sino Medical Sciences Technology In is 20.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sino Medical Sciences Technology In (688108)?
Revenue at Sino Medical Sciences Technology In is growing +18.1% versus a year earlier (3y avg +39.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sino Medical Sciences Technology In (688108)?
Earnings per share at Sino Medical Sciences Technology In are growing +245% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Sino Medical Sciences Technology In (688108) hold?
Sino Medical Sciences Technology In holds more cash than debt, 165M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Sino Medical Sciences Technology In in the live analysis
One click puts Sino Medical Sciences Technology In on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Some data
Oct 28, 2026